Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
about
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Deferasirox for the treatment ...... ter phase I study (KSGCT1302).
@en
Deferasirox for the treatment ...... ion: multicenter phase I study
@nl
type
label
Deferasirox for the treatment ...... ter phase I study (KSGCT1302).
@en
Deferasirox for the treatment ...... ion: multicenter phase I study
@nl
prefLabel
Deferasirox for the treatment ...... ter phase I study (KSGCT1302).
@en
Deferasirox for the treatment ...... ion: multicenter phase I study
@nl
P2093
P2860
P50
P1476
Deferasirox for the treatment ...... ter phase I study (KSGCT1302).
@en
P2093
Eri Yamamoto
Heiwa Kanamori
Junya Kanda
Kanto Study Group for Cell Therapy (KSGCT)
Masatsugu Tanaka
Satoshi Koyama
Satoshi Morita
Shinichiro Machida
Shinichiro Okamoto
Takeshi Saito
P2860
P2888
P304
P356
10.1007/S12185-017-2396-9
P577
2018-01-05T00:00:00Z